Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2565-2571

  Beetstra, Sasja ^a,c   Suthers, Graeme ^b   Dhillon, Varinderpal ^a   Salisbury, Carolyn ^a   Turner, Julie ^a   Altree, Meryl ^b   McKinnon, Ross ^a   Fenech, Michael ^a,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYANOCOBALAMIN; HOMOCYSTEINE; METHIONINE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CELL COUNT; CELL CULTURE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; PHENOTYPE; PRIORITY JOURNAL;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 54249159371     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0140     Document Type: Article

References (48)

1. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
2. Ogier G, Chantepie J, Deshayes C, et al. Contribution of 4-methylthio-2-oxobutanoate and its transaminase to the growth of methionine-dependent cells in culture. Effect of transaminase inhibitors. Biochem Pharmacol 1993;45:1631-44.
3. Stern PH, Mecham JO, Wallace CD, Hoffman RM. Reduced free-methionine in methionine-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 1983;117:9-14.
4. James SJ, Yin L, Swendseid ME. DNAstrand break accumulation, thymidylate synthesis and NAD levels in lymphocytes from methyl donor-deficient rats. J Nutr 1989;119:661-4.
5. Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 1983;117:429-34.
6. Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 1984;119:29-34.
7. Carson DA, Willis EH, Kamatani N. Metabolism to methionine and growth stimulation by 5′-methylthioadenosine and 5′-methylthioinosine in mammalian cells. Biochem Biophys Res Commun 1983;112:391-7.
8. Crott J, Thomas P, Fenech M. Normal human lymphocytes exhibit a wide range of methionine-dependency which is related to altered cell division but not micronucleus frequency. Mutagenesis 2001;16:317-22.
9. Hall CA, Begley JA, Chu RC. Methionine dependency of cultured human lymphocytes. Proc Soc Exp Biol Med 1986;182:215-20.
10. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49.
11. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-82.
12. Mikol YB, Lipkin M. Methionine dependence in skin fibroblasts of humans affected with familial colon cancer or Gardner's syndrome. J Natl Cancer Inst 1984;72:19-22.
13. Miki Y, Swensen J, Shattuck-Eidens D, et al. Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
14. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
15. Schwab M, Claas A, Savelyeva L. BRCA2: a genetic risk factor for breast cancer. Cancer Lett 2002;175:1-8.
16. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J Cell Physiol 2003;196:19-41.
17. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28-33.
18. van der Put NM, Gabreels F, Stevens EM, et al. Asecond common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
19. Frosst P, Blom HJ, Milos R, et al. Acandidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
20. NHMRC. Familial aspects of cancer: a guide to clinical practice. Canberra: Australian government publishing services; 1999.
21. Suthers GK, Armstrong J, McCormack J, Trott D. Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet 2006;43:665-70.
22. Evans DG, Eccles DM, Rahman N, et al. Anew scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
23. Beetstra S, Salisbury C, Turner J, et al. Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency. Carcinogenesis 2006;27:517-24.
24. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. Asecond genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
25. Wakutani Y, Kowa H, Kusumi M, et al. A haplotype of the methylenetetrahydrofolate reductase gene is protective against late-onset Alzheimer's disease. Neurobiol Aging 2004;25:291-4.
26. van der Put NM, van der Molen EF, Kluijtmans LA, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM 1997;90:511 - 7.
27. Janosikova B, Pavlikova M, Kocmanova D, et al. Genetic variants of homocysteine metabolizing enzymes and the risk of coronary artery disease. Mol Genet Metab 2003;79:167-75.
28. Pallant J. SPSS survival manual: a step by step guide to data analysis using SPSS. Crows Nest: Allen & Unwin; 2005.
29. Duthie SJ, Narayanan S, Sharp L, et al. Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc 2004;63:571-8.
30. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006;131:1271-83.
31. Christa L, Kersual J, Auge J, Perignon JL. Salvage of 5′-deoxy-5′-methylthioadenosine and L-homocysteine into methionine in cells cultured in a methionine-free medium: a study of "methionine- dependence". Biochem Biophys Res Commun 1986;135:131-8.
32. Kramer DL, Sufrin JR, Porter CW. Relative effects of S-adenosylmethionine depletion on nucleic acid methylation and polyamine biosynthesis. Biochem J 1987;247:259-65.
33. Judde JG, Ellis M, Frost P. Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 1989;49:4859-65.
34. Kimura M, Umegaki K, Higuchi M, Thomas P, Fenech M. Methylenetetrahydrofolate reductase C677T polymorphism, folic acid and riboflavin are important determinants of genome stability in cultured human lymphocytes. J Nutr 2004;134:48-56.
35. Lissowska J, Gaudet MM, Brinton LA, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer 2007;120:2696-703.
36. Pepe C, Guidugli L, Sensi E, et al. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Res Treat 2007;103:29-36.
37. Xu X, Gammon MD, Zhang H, et al. Polymorphisms of one-carbon metabolizing genes and risk of breast cancer in a population-based study. Carcinogenesis 2007;28:1504-8.
38. Shrubsole MJ, Gao YT, Cai Q, et al. MTR and MTRR polymorphisms, dietary intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:586-8.
39. Justenhoven C, Hamann U, Pierl CB, et al. One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Biomarkers Prev 2005;14:3015-8.
40. Li SY, Rong M, Iacopetta B. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer. Oncol Rep 2006;15:221-5.
41. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-41.
42. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34.
43. Suzuki T, Matsuo K, Hirose K, et al. One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis 2008;29:356-62.
44. Langsenlehner T, Renner W, Yazdani-Biuki B, Langsenlehner U. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 2008;107:459-60.
45. Macis D, Maisonneuve P, Johansson H, et al. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat 2007;106:263-71.
46. Jakubowska A, Gronwald J, Menkiszak J, et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 2007;104:299-308.
47. Shrubsole MJ, Gao YT, Cai Q, et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2004;13:190-6.
48. Campbell IG, Baxter SW, Eccles DM, Choong DY. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002;4:R14.